anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject composition having good stable preservability and solubility along with an excellent processability by including e.g. a trovafloxacin mesylate in the form of polymorph II. SOLUTION: This composition comprises (A) a trovafloxacin mesylate, (B) a lubricant and (C) at least 5% of microcrystalline cellulose. It is pref. in the form of tablets which satisfy USP Stage 1 (S1 ) Allowance Standard, have a hardness of 8 kP and further comprise (D) a film coating of e.g. hydroxypropyl cellulose and (E) a disintegrant, specifically the tablets comprise 52.7% of the component A, 36.8% of the component C, 4.8% of croscarmellose sodium, 1.9% of magnesium stearate and 3.8% of the component D.
BACKGROUND: The systemic immune-inflammation index (SII) and trouble sleeping are independent risk factors for nonalcoholic fatty liver disease (NAFLD). Nevertheless, studies investigating the combined effects of the SII and troubled sleeping on NAFLD are lacking. In this study, we investigated the independent relationships and interactions between trouble sleeping and the SII among patients with NAFLD.
METHODS: Data from seven survey cycles of the National Health and Nutrition Examination Survey (NHANES) (2005-2018) were analyzed. The SII was obtained by counting platelets, neutrophils, and lymphocytes. NAFLD was diagnosed using the US fatty liver index. Trouble sleeping was diagnosed using a sleep disorder questionnaire. The correlation between trouble sleeping and the SII in NAFLD was investigated using multiple regression analysis, subgroup stratification, interaction tests, and restricted cubic spline, and the presence or absence of additive or multiplicative interactions was determined. Additionally, mediation analyses were performed to explore the role of the SII in mediating the effects of trouble sleeping on NAFLD.
RESULTS: The survey included 10 963 participants. Multivariate logistic regression revealed that SII (OR: 1.21, 95% CI 1.08-1.35) and trouble sleeping (OR: 1.24, 95% CI 1.05-1.47) were positively correlated with NAFLD. For NAFLD, an additive but not multiplicative interaction was noted between the SII and trouble sleeping. The SII partially mediated the association between trouble sleeping and NAFLD, accounting for approximately 3.11% of the total effect (95% CI 0.01-0.05).
CONCLUSION: The SII and trouble sleeping were independently correlated with NAFLD risk. Furthermore, a combined effect may exist between SII and trouble sleeping, which increases the risk of NAFLD.
Pre-test (PVQ and PedsQL) will be applied after obtaining informed consent from the parents included in the control group after randomization. In the pre-test application, an interim evaluation (PVQ and PedsQL) will be applied to the control group 1 week after and the post-test (PVQ and PedsQL) will be applied 4 weeks later. After the post-test application is completed, a five-day individual interview will be applied to the parents included in the control group.
The treatment model takes into account the patient's perception disorders. This means e.g. an adapted mealtime situation where the patient can eat separately or wear hearing protection if necessary. The patients have an adapted meal plan regarding difficulties with specific textures or foods. To meet their need for continuity, they have the same contact persons throughout the entire period of care. The healthcare staff receive training in working with the specific subgroup and have regular exchanges of experience regarding the patient group, 15 minutes every or every two weeks.
Nephrotic syndrome is characterized by the leakage of protein from the blood into the urine along with the triad of proteinuria, albuminuria, and peripheral edema. Loss of protein leads to the loss of immunoglobulin and complements. X-linked agammaglobulinemia (XLA), or Bruton disease, is a primary immunodeficiency disease caused by a defect in the development of B cells in the bone marrow and a low serum level of immunoglobulins. The present case involves a 12-year-old boy with nephrotic syndrome, osteomyelitis, and recurrent infections. We discovered that he had XLA. This report underscores the importance of considering inborn errors of immunity in cases of protein loss, such as nephrotic syndrome.
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, solvate or isomers and mixtures thereof. The invention further relates to a process for the stereoselective preparation of such compounds. The compound of formula (I) can be used as a medicament, in particular for inhibiting coronin 1 expression in the induction of immunosuppression or in the treatment and/or prevention of a disease or disorder selected from the group consisting of transplant rejection, autoimmune diseases, inflammatory diseases, infectious diseases, and lymphoproliferative disorders. The present invention further relates to a vector comprising a coronin 1 promoter element, wherein in a vertebrate genome, said coronin 1 promoter element starts directly upstream from a transcription starting site (TSS) of a coronin 1 gene and spans a sequence stretch of at least about 700 bp in said genome. The present invention further relates to a method using said vector for identifying immunomodulatory compounds that alter the coronin 1 promoter activity. The present invention further relates to BRD3 as an upstream target responsible for driving the coronin-1 expression and activity in immune cells, and relates to compounds, in particular compound of formula (I), that selectively target bromodomains of BRD3 and thereby deplete coronin 1 levels.
The invention discloses viscera cleaning traditional Chinese medicine for diminishing inflammation and removing toxic materials and a preparing method of the viscera cleaning traditional Chinese medicine. The viscera cleaning traditional Chinese medicine is prepared through a formula including 21 kinds of unique traditional Chinese medicine such as honeysuckle, isatis roots, rheum officinale, codonopsis pilosula, fructus amomi, malt and bighead atractylodes rhizome. The viscera cleaning traditional Chinese medicine has the five comprehensive advantages of clearing away heat to remove toxic materials, dispelling fatigue to remove toxic materials, dispelling damp to remove toxic materials, cleaning the blood to remove toxic materials and strengthening the body resistance to remove toxic materials. All exterior and interior pathogenic factor toxic materials can be cleared away, pathogenic factors can be dispelled, the body resistance can be strengthened, and the body health can be maintained. The viscera cleaning traditional Chinese medicine can be used for treating the pneumonia, trachitis, myocarditis, splenauxe, acute and chronic hepatitis, gastroenteritis, nephritides, urocystitis, prostatitis, pharyngitis, encephalitis, cardiovascular and cerebrovascular diseases and other viscera miscellaneous internal diseases and treating vasculitis, osteomyelitis, arthritis and other limb inflammations, has the special effect on viral infection, has the treating effect on arteriosclerosis, and is suitable for treating aged patients. The viscera cleaning traditional Chinese medicine is ideal broad spectrum medicine for clearing away heat to remove toxic materials and conditioning the viscera.
Manualized group treatment of parents. Allocation of 4-6 parental couples of children with similar age.
Participants randomized into this group will complete all measurement sessions. After completion of the final measurement session (6 months), participants will be offered an abbreviated version of the Life Style and Sleep Group intervention including the sleep hygiene course, consultation with sleep expert to go over individual sleep patterns and be given recommendations, along with physical activity recommendations from a fitness expert.
PURPOSE: A method for extracting 5-hydroxymethyl-2-furfural from Lonicera japonica THUNB. is provided. The 5-hydroxymethyl-2-furfural has inhibition effect on the formation of hepatitis B surface antigen, and is thus useful for treatment of hepatitis B. CONSTITUTION: A method for extracting 5-hydroxymethyl-2-furfural from Lonicera japonica THUNB. comprises the steps of: boiling Lonicera japonica THUNB. in water of 60 to 90 deg. C for 12 to 48 hours to prepare an extract of Lonicera japonica THUNB.; subjecting the Lonicera japonica THUNB. extract to a hydrophobic phenyl Sepharose chromatography using 10%(v/v) acetonitrile as eluent and C18 column; and subjecting a fraction of the hydrophobic phenyl Sepharose chromatography to a reverse phase high pressure liquid chromatography using a mixed solution of acetonitrile and water containing 0.1% trifluoroacetic acid as eluent to collect a fraction corresponding to 5-hydroxymethyl-2-furfural.
A vitamin K animal feed premix having improved stability to air, heat, moisture, acid and dilute alkalis, contains at least 2 grams per pound of a menadione bisulphite adduct of menadione and a water sol. bisulphite and from 2 to 50 wt. % of a non-toxic acid-reductone, based on menadione bisulphite. The aci-reductone may be aliphatic, alicyclic or an equivalent salt, ester or lactone such as Ca or Na erthorbate, diethyl dihydroxy maleate or Ca ascorbate. The feeds are esp. useful for preventing haemorrhagic disese disease in poultry.
Patients who recieve hyperbaric oxygen therapy will be maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
In toxicology studies conducted in neonatal mice, dose-dependent cardiac and hepatic toxicities were observed following intravenous administration of onasemnogene abeparvovec. Onasemnogene abeparvovec-related findings in the myocardium, at doses of 7.9 × 1013 vg/kg and higher, included slight to mild mononuclear cell inflammation accompanied by edema, slight to mild fibrosis, and scattered myocardial cell degeneration/regeneration. Additional cardiac findings at dose levels of 1.5 × 1014 vg/kg and higher included minimal to moderate atrial thrombosis and slight to marked atrial dilation. Liver findings included hepatocellular hypertrophy, Kupffer cell activation, perinuclear vacuolation, and scattered hepatocellular necrosis. Target organ toxicity in the heart and liver was associated with mortality in mice at dose levels of 2.4 × 1014 vg/kg and above, approximately 2.2-fold higher than the recommended clinical dose level.

In a 6-month toxicology study conducted in juvenile non-human primates, single intravenous administration of onasemnogene abeparvovec at the recommended clinical dose level of 1.1 × 1014 vg/kg, with or without corticosteroid treatment, resulted in microscopic findings in the dorsal root ganglia (DRG), trigeminal ganglia (TG), spinal cord, brainstem, and liver. At 6 weeks post-administration, microscopic findings included minimal to slight mononuclear cell inflammation and neuronal degeneration in the DRG and TG; axonal degeneration and gliosis in the spinal cord; mixed cell inflammation, gliosis, and axonal degeneration in the brainstem; and oval cell hyperplasia in the liver. These microscopic findings were still present at 6 months with decreased severity and incidence.
Period 1: randomized to either fasting IR or ER2. Period 2: Cross-over to either IR or ER2. Period 3: ER2 in fed conditions.
PURPOSE:To obtain a remedy for circulatory diseases, having plural pharmacological actions to the circulatory system, and capable of integrally curing the diseases which are often interacted complicately with each other, by using 5- hydroxydecanoic acid, its salt, etc. as an active component. CONSTITUTION:The objective remedy contains, as active component, 5-hydroxydecanoic acid of formula I , its salt, its ester and/or its lactone i.e. delta-decalactone of formula II. The compound has the remedying effect to hyperlipemia which causes arteriosclerosis, the suppressing effect to the mitochondrial dysfunction which is an ischemic disorder, and the antiarrhythmic activity free from cardioinhibitory action, as independent activities, and is useful for the integral remedy for circulatory diseases with complications, and remedy for individual diseases such as arteriosclerosis, aschemic cardiopathy, cardiac insufficiency, shock, cerebrovascular disorder, arrhythmia, etc. Dose: preferably 100-5,000mg for oral administration and 5-500mg for injection daily for adult.
PURPOSE: A composition and a cosmetic composition containing Myristicae Semen extract are provided to suppress pancreatic cancer cell growth and to effectively prevent and treat pancreatic cancer. CONSTITUTION: A composition for preventing and treating pancreatic cancer contains Myristicae Semen extract as an active ingredient. The extract is extracted from Myristicae Semen fruits using water, low carbon number alcohol, acetone, chloroform, methylene chloride, ether, ethyl acetate, and hexane at 50 Deg. C. for 24 hours. The composition also contains pharmaceutically acceptable carriers or diluents. The pancreatic cancer is pancreatic ductal adenocarcinoma. A cosmetic composition containing Myristicae Semen ethanol extract contains the extract and cosmetologically acceptable cosmetic additives. [Reference numerals] (AA) Relative cell survival rate
One physician visit at Puentes de Salud or Congreso Health Center to discuss healthy lifestyle behaviors that promote weight loss and diabetes prevention. During that visit, UC participants will also receive standard educational materials in Spanish from the NIDDK Weight-control Information Network covering the same topics. UC participants will receive another physician visit upon completion of 1-year follow-up to review laboratory assessments.
Lung transplantation currently is one way to treat a variety of serious diseases and conditions such as emphysema, pulmonary fibrosis, and cystic fibrosis. Ischemia Reperfusion Injury (IRI) is a known problem that can happen during the first few days after a lung transplant. IRI can cause swelling of the lungs and low levels of oxygen. The most serious type of IRI can cause the transplanted lung to not work properly, it can even cause death. While new treatments and practices have been put into place to lower the chances of IRI, it is still a difficult problem to overcome after a lung transplant.

Molecule called Adenosine 2A receptor (A2AR) have been studied in animals with IRI for many years. Some of these studies suggest that with the use of A2AR agonist, the chance of IRI may be lowered or prevented. Regadenoson is a selective A2AR agonist.
A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed 0.25% bupivacaine at a dose of 0.2 ml/kg was administered.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease (COVID-19), induced a global pandemic with a diverse array of clinical manifestations. While the acute phase of the pandemic may be waning, the intricacies of COVID-19's impact on neurological health remain a crucial area of investigation. Early recognition of the spectrum of COVID-19 symptoms, ranging from mild fever and cough to life-threatening respiratory distress and multi-organ failure, underscored the significance of neurological complications, including anosmia, seizures, stroke, disorientation, encephalopathy, and paralysis. Notably, patients requiring intensive care unit (ICU) admission due to neurological challenges or due to them exhibiting neurological abnormalities in the ICU have shown increased mortality rates. COVID-19 can lead to a range of neurological complications such as anosmia, stroke, paralysis, cranial nerve deficits, encephalopathy, delirium, meningitis, seizures, etc., in affected patients. This review elucidates the burgeoning landscape of neurological sequelae associated with SARS-CoV-2 infection and explores the underlying neurobiological mechanisms driving these diverse manifestations. A meticulous examination of potential neuroinvasion routes by SARS-CoV-2 underscores the intricate interplay between the virus and the nervous system. Moreover, we dissect the diverse neurological manifestations emphasizing the necessity of a multifaceted approach to understanding the disease's neurological footprint. In addition to elucidating the pathophysiological underpinnings, this review surveys current therapeutic modalities and delineates prospective avenues for neuro-COVID research. By integrating epidemiological, clinical, and diagnostic parameters, we endeavor to foster a comprehensive analysis of the nexus between COVID-19 and neurological health, thereby laying the groundwork for targeted therapeutic interventions and long-term management strategies.
Therapist approaches the desired level of spinous process from medial aspect of the thumb of one hand which is reinforced by the index finger of the other hand. Second therapist places his axilla over the patient's shoulder to add shoulder depression component. The second therapist performs components of the nerve to be test one by one (distal to proximal or proximal to distal sequence) depending upon patient's offending movements and painful range.Pure transverse glide is performed from affected to unaffected side. While the glide is sustained, another therapist mobilizes the median nerve by performing desired neurodynamic sliding movement. Apply this protocol for 4 weeks 12 Sessions (3 sessions in a week) and 10 sec rest between each segment, 3 sets of 10 repetitions.
Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is one of the common causes of euvolemic hyponatremia (serum Na+ < 135 mEq/L) in hospitalized children. It is characterized by increased serum ADH, leading to water retention via its action on V2 receptors in the distal renal tubules. Various conditions such as pain, the postoperative state, drugs, central nervous system infections, tumors, malformations, and pneumonia can predispose a person to SIADH. The conventional treatment of SIADH includes fluid restriction and salt supplementation. Occasionally, this may fail to control hyponatremia, mandating pharmacological therapy. V2-receptor antagonists are an FDA-approved therapy for adults with euvolemic and hypervolemic hyponatremia. However, there is limited experience with their use in the pediatric population. Here, the authors present a girl with corpus callosum agenesis with severe symptomatic hyponatremia due to SIADH who was successfully managed with the V2-receptor antagonist tolvaptan.
After intensive chemotherapy, the emergence of cells with dmg resistant and/or stem cell features might explain frequent relapses and the poor outcome of patients with acute myeloid leukemia (AML). Herein the inventors first uncovered that the adrenomedullin receptor CALCRL is overexpressed in AML patients comparing with normal cells and preferentially in the immature CD34+ CD38− compartment. Then they demonstrated its role in the maintenance of leukemic stem cell function in vivo. Moreover, CALCRL depletion strongly affected leukemic growth in xenograft models and sensitized to chemotherapeutic agent cytarabine in vivo. It Accordingly, the inventors showed that ADM-CALCRL axis drove cell cycle, DNA integrity, and high OxPHOS status of chemoresistant AML stem cells in an E2F1- and BCL2-dependent manner. Furthermore, CALCRL depletion sensitizes cells to cytarabine and its CT expression predicted the response to chemotherapy in vivo in mice. Further, using the combination of limiting dilution assays, single-cell RNA-seq analysis of primary AMF samples at diagnosis and relapse and before and after transplantation in NSG mice, the inventors revealed the pre-existence of a chemoresistant leukemic stem cell sub-population harboring a CALCRL-driven gene signature. Finally the inventors strongly demonstrated that chemoresistant LSC are dependent for CALCRL. All of these data highlight the critical role of CALCRL in stem cell survival, proliferation and metabolism and identify this receptor as a new marker of chemoresistant leukemic stem cell population and a promising therapeutic target to specifically eradicate them and overcome relapse in AML.
The prevalence of methicillin resistant Staphylococcus aureus (MRSA) respiratory infection in patients with cystic fibrosis has increased dramatically over the last decade. Epidemiologic evidence suggests that persistent infection with MRSA may result in an increased rate of decline in FEV1 and shortened survival. Treatment of MRSA is a top priority. Inhaled antibiotics offer the advantage of high concentrations of antibiotic at the site of infection (the airway) while minimizing systemic side effects. Vancomycin is a glycopeptide antibiotic that has activity against MRSA. Anecdotal and retrospective peer-reviewed studies have demonstrated that inhaled vancomycin is safe and potentially effective in patients with cystic fibrosis and MRSA airway infection. Data evaluating the pharmacokinetics of vancomycin in sputum are needed before pursuing treatment trials.
The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.
ELCYS® must be diluted and used as an admixture in PN solutions. It is not for direct intravenous infusion. Solutions with an osmolarity of 900 mOsm/L or greater must be infused through a central catheter [see Dosage and Administration (2.1)]. The infusion of hypertonic nutrient injections into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.
This is a prospective, multicenter, observational, follow-up study to evaluate the long-term safety of RGX-111 after a single administration. Eligible participants are those who previously participated in a clinical study where they received a single IC or ICV administration of RGX-111. Enrollment of each participant in this study should occur on the same day or after the participant has completed the end of study (EOS) visit or early discontinuation visit (EDV) from a previous (parent) clinical study. Participants will be followed for up to five years after RGX-111 administration (inclusive of the parent study) or until RGX-111 is commercially available in the participant's country, whichever occurs first. No treatment will be directed under this observational protocol. The total study duration for each participant may vary depending on when s/he enrolls in the current study following RGX-111 administration in the parent study.
This is a phase I open label, non-placebo controlled trial evaluating the safety and efficacy of natalizumab in patients with IBM. Pre and post treatment muscle biopsies including measurements of the degree of inflammation as well as the types of inflammatory cells will be measured. The investigators will also assess quality of life, the inclusion body myositis functional rating score (IBM-FRS), and patient and physician global impression of change. Manual muscle testing and quantitative dynamometry will also be evaluated to see if patient's strength improves.

Patients who are eligible to participate and have signed a consent form will have a muscle biopsy performed at baseline and at the end of the study. Physical and neurological exams, as well as IBM-FRS, safety labs will be conducted and collected at monthly visits. Patients will start natalizumab therapy at 300mg intravenously every 4 weeks for 24 weeks. All study related procedures will be conducted at Phoenix Neurological Associates, as well as all infusions and muscle biopsies